Steady-state Pharmacokinetics of Efavirenz (Sustiva/Stocrin) 400 mg Once Daily in the Presence of Rifampicin and Isoniazid (Rifinah or the Local Generics)

Trial Profile

Steady-state Pharmacokinetics of Efavirenz (Sustiva/Stocrin) 400 mg Once Daily in the Presence of Rifampicin and Isoniazid (Rifinah or the Local Generics)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Efavirenz (Primary) ; Emtricitabine; Isoniazid; Lamivudine; Rifampicin; Tenofovir; Zidovudine
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 26 Jul 2017 Results of effects of efavirenz in women living with HIV (WLWH) during third trimester of pregnancy and post-partum (n=22) presented at the 9th International AIDS Society Conference on HIV Science
    • 20 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.
    • 20 Jun 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top